A weekly update on interesting numbers in product liability, class action and mass tort news from June 30–July 6. Published Fridays. 5 and 1/2 years The age of a user tracking case against Facebook, dismissed for the second time on July 3rd. The $15 billion multidistrict litigation case claimed that Facebook tracked data on users when they visited sites outside Facebook that had Facebook “like” buttons. U.S. District Judge Edward Davila said the plaintiffs failed to establish that they had...Continue Reading
A weekly update on interesting numbers in product liability, class action and mass tort news from June 23–June 29. Published Fridays. 5 days The length of time a court in California allocated to determine which expert witnesses will testify in the upcoming Johnson & Johnson talc trial. More than 300 plaintiffs in the state of California allege that use of Johnson & Johnson’s talc products caused ovarian cancer. Previous trials in Missouri concerning talc’s connection to ovarian cancer have awarded...Continue Reading
There has been a lot of media attention on the issue of transvaginal mesh implants lately, and more and more women have become aware of the implications of using this surgical implant. In 2008, the FDA issued a notice informing the public of the growing number of complications being reported. They issued an update in 2011 notifying the public that the condition POP can be treated successfully without mesh, therefore avoiding the risk complications that are mesh-related but that announcement...Continue Reading
Over the past decade, there has been a growing debate over the risks associated with inferior vena cava filters, commonly known as IVC filters. These filters are implanted in patients who suffer from blood clot complications to reduce the risk of pulmonary embolism, blood clots and deep vein thrombosis. However, studies have shown that extended retention of IVC filters in the body may increase the risk of blood clot as well as injury to organs. What is an IVC filter?...Continue Reading
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a group of FDA-approved drugs used to treat low blood sugar in adults suffering from Type-2 diabetes. However, in 2015, the FDA issued a warning that Invokana and other SGLT2 inhibitors can trigger a condition known as diabetic ketoacidosis (DKA). This condition is caused by very high levels of acid in blood. In addition, the FDA has also warned that SGLT2 inhibitors can cause kidney injuries, bone fractures, breast and bladder cancer and pancreatitis among...Continue Reading
Speak with a Lawyer
Contact an attorney today for a free and confidential legal consultation.